Boehringer Ingelheim receives FDA approval for its Humira biosimilar

Cyltezo approved for the treatment of multiple chronic inflammatory diseases.

These diseases include the following:

"Cyltezo is the first biosimilar from Boehringer Ingelheim to be approved by the FDA and marks an important step towards our goal of providing new and more affordable treatment options to healthcare providers and patients," said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim. "Chronic inflammatory diseases collectively affect 23.5 million people in the US, and Cyltezo™ has the potential to deliver significant benefits to many of these individuals."

The FDA approval is based on a comprehensive data package comprised of analytical, pharmacological, non-clinical and clinical development studies demonstrating that Cyltezo is biosimilar to Humira.

The European Medicines Agency is expected to provide an opinion on the marketing authorization application for our biosimilar candidate in 2017.

Cyltezo is not commercially available at this time. Boehringer Ingelheim is currently engaged in patent litigation with AbbVie. Boehringer Ingelheim will also seek approval for an auto-injector of Cyltezo, as another delivery option for patients.